|

Trastuzumab and Pertuzumab Clinical Trials

2 actively recruiting trials across 1 location

Also known as: Herceptin and Perjeta

Pipeline

Phase 2: 1Phase 3: 1

Top Sponsors

  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University1
  • American Society of Clinical Oncology1

Indications

  • Cancer2
  • Neratini1
  • RCB Classification 1-21
  • Adjuvant Treatment After Trastuzumab1
  • Early-stage Breast Cancer1

Other1 trial

Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab
Phase 3

Birmingham, Alabama1 trial

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

University of Alabama at Birmingham Comprehensive Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.